Biocon Biologics Secures Japanese Approval for Pegfilgrastim Biosimilar
核心洞察
Biocon Biologics (搜索) received marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, a cancer supportive care medicine.
The product, a biosimilar to Neulasta, is designed to prevent infections following chemotherapy and will be exclusively promoted, sold, and distributed in Japan by Sandoz KK (搜索).
Global Regulatory Partners Japan (搜索) serves as the marketing authorization holder on behalf of Biocon, with the product developed and manufactured by Biocon Biologics (搜索) Ltd.
Biocon Biologics (搜索), a wholly-owned subsidiary of Biocon Ltd, has received marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, a cancer supportive care medicine used to prevent infections after chemotherapy. The approval, announced on Tuesday, marks a pivotal step in expanding Biocon's biosimilar range and improving patient accessibility worldwide.
The product is a biosimilar to Neulasta and is developed and manufactured by Biocon Biologics (搜索) Ltd, the parent entity of Biocon Biologics UK PLC. Global Regulatory Partners Japan (搜索) serves as the marketing authorization holder on behalf of Biocon, according to the company's regulatory filing.
Commercialization and Distribution
Sandoz KK (搜索) will exclusively promote, sell, and distribute the product in Japan. This arrangement positions the pegfilgrastim biosimilar as a direct rival to Neulasta within the Japanese market, with Sandoz KK managing the commercial footprint.
Strategic Significance
The approval further strengthens Biocon's portfolio of biosimilar products in Japan and reaffirms the company's commitment to increasing patient access to high-quality and affordable medications globally. The pegfilgrastim biosimilar addresses a vital supportive care need by mitigating infection risks in patients undergoing chemotherapy, underscoring its clinical relevance in oncology care.